Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy

Brachat A. H., Grom A. A., Wulffraat N., Brunner H. I., Quartier P., Brik R., ...More

ARTHRITIS RESEARCH & THERAPY, vol.19, 2017 (SCI-Expanded) identifier identifier identifier


Background: Canakinumab is a human anti-interleukin-1 beta (IL-1 beta) monoclonal antibody neutralizing IL-1 beta-mediated pathways. We sought to characterize the molecular response to canakinumab and evaluate potential markers of response using samples from two pivotal trials in systemic juvenile idiopathic arthritis (SJIA).